ClinicalTrials.gg
CompletedNCT00002253Updated Jun 24, 2005

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

An interventional study of Octreotide in Diarrhea and HIV Infections, sponsored by Sandoz. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Sandoz (formerly part of Novartis) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Diarrhea by Novartis — none open to participants now, none under way, none of them phase 3. Diarrhea · Novartis.

No phase
2 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Diarrhea by Novartis, this one is one of 2 with no phase, and was the 1st registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

None of the 13 studies in Diarrhea by Novartis is open now. The open studies under Diarrhea, anywhere →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Diarrhea by Novartis as a file.
02

Study summary

The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A).

The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were "Non-Responders" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in "Responders" from Study #D03 - FDA 102A.

03

Conditions studied

  • Diarrhea
  • HIV Infections

Keywords

  • Octreotide
  • Diarrhea
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

Patients must have the following:

  • Only patients who have completed the duration of Study D203, FDA 102A will be eligible for this study.
  • Each of these patients must give written to participate in Study D204, FDA 102B as well.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

22 sites
  • USC School of Medicine
    Los Angeles, California 90033, United States
  • UCSD Med Ctr
    San Diego, California 92103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • San Mateo County Gen Hosp
    San Mateo, California 94403, United States
  • Med Service
    Miami, Florida 33125, United States
  • Emory Univ School of Medicine
    Atlanta, Georgia 30303, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Maine Med Ctr Med Clinics
    Portland, Maine 04102, United States
  • Douglas Plesko
    Boston, Massachusetts 02115, United States
  • Boston City Hosp
    Boston, Massachusetts 02118, United States
  • Henry Ford Hosp
    Detroit, Michigan 48202, United States
  • Univ of Missouri at Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • SUNY Stony Brook / Health Sciences Ctr
    Stony Brook, New York 117948121, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Buckley Braffman Stern Med Associates
    Philadelphia, Pennsylvania 19107, United States
  • Miriam Hosp / Family Healthcare Ctr at SSTAR
    Providence, Rhode Island 02906, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77550, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22203, United States
  • Univ of Wisconsin School of Medicine
    Madison, Wisconsin 53792, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002253
Lead sponsor
Sandoz
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 1992. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion